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Abstract
Background: Hypophosphatasia (HPP) is a rare, inherited, metabolic disease caused by tissue-nonspecific
alkaline phosphatase deficiency, characterized by bone mineralization defects and systemic complications.
Understanding of the clinical course and burden of HPP is limited by its rarity. This systematic literature
review and synthesis of case report data aimed to determine the frequency and timing of clinical HPP
manifestations and events.
Methods: Case reports and series of patients with HPP who had been followed longitudinally for ≥1 year
were identified. Demographics and clinical data of interest, identified through consultation with clinical
experts in HPP, were extracted. Occurrences of clinical manifestations/events of interest were categorized,
classified by age at first reported occurrence of HPP manifestations and visualized over time. Clinical
manifestations/events considered to contribute to the clinical burden of HPP were identified. Kaplan–Meier
curves were used to estimate the median (range) age at first occurrence of the most frequently reported
manifestations/events.
Results: From the 283 studies that met the inclusion criteria, 265 patients with HPP with ≥1 year of longitudinal follow-
up were identified (median [interquartile range] age 4 [0–34] years; 45% male). The types of clinical manifestations/events
of interest experienced by individuals with ≥1 such manifestation/event (n = 261) often differed between older and
younger patients. Most (94%) of the 265 patients experienced ≥1 manifestation/event deemed to contribute to the
clinical burden of HPP; premature tooth loss (53.5%), fractures (35.8%), pain (33.6%), and gross motor/ambulation
difficulties (30.9%) were most frequently reported. The median (range) age at first reported occurrence of respiratory
symptoms, cranial abnormalities, and premature tooth loss ranged from 0.3 to 10 years, whereas the median age at first
reported occurrence of fractures, pain, gross motor/ambulation difficulties, and surgery ranged from 33 to 70 years.
Conclusions: HPP is associated with a high clinical burden of disease, regardless of age at first reported occurrence of
HPP manifestations. Over an individual’s lifetime, the types of manifestations/events experienced can change and multiple
HPP-related clinical manifestations/events can accumulate. These observations may reflect evolution and progression of
the disease.
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Background
Hypophosphatasia (HPP) is a rare, systemic, genetic,
metabolic disease caused by deficient activity of the
tissue non-specific isoenzyme of alkaline phosphat-
ase, resulting in the extracellular accumulation of its
substrates [1]. The clinical presentation of HPP can
vary considerably between individuals and includes
skeletal problems, muscle weakness, ambulatory diffi-
culties, pain, and dental, neurologic, and renal mani-
festations [2]. Historically, HPP has been classified
based on age at first manifestation of the disease,
into perinatal, infantile, childhood, and adulthood
HPP [3]. HPP identified in patients in the perinatal
and infantile periods is associated with significant
mortality [4]. Those who survive, and those who
present with the disease later, may show manifesta-
tions of HPP that include poor growth [5–8], delay
in reaching motor milestones [6, 9, 10], muscle
weakness [7, 8], pain [11, 12], dental abnormalities
[13], and low-trauma fractures [7, 14]. These clinical
manifestations often lead to ambulatory difficulties
that can restrict activities of daily living, which can
contribute to the high burden of disease seen among
patients with HPP [7]. In addition, the chronic and
heterogeneous nature of the condition means clinical
manifestations experienced by individual patients can
change over time. For example, some patients who
have a history of only odontohypophosphatasia
(odonto-HPP) during childhood may develop skeletal
manifestations during adulthood [15].
Case reports and case series describing selected out-
comes for approximately 500 cases of HPP have been
published; however, knowledge of the overall clinical
course of HPP is limited. To date, no robust, long-term
observational studies assessing the natural history, clin-
ical progression, or outcomes in patients with HPP have
been published. Although case reports and case series
include data that are not collected in a standardized
fashion, they provide a rich source of information about
the clinical manifestations patients’ experience at differ-
ent ages. A synthesis of case report data may increase
our understanding of the natural history of the disease.
The aim of this systematic literature review and syn-
thesis of patient case report data was to determine the
frequency and timing of key clinical manifestations and
events of HPP.
Methods
Systematic literature review
A systematic review of the literature was conducted ac-
cording to best practices, and following Preferred
Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines [16]. A customized
search strategy including the terms ‘hypophosphatasia’
and ‘HPP’ was implemented in PubMed/MEDLINE and
Embase (from the inception of the databases in 1950
and 1947, respectively, to February 2017) to identify
studies of patients with HPP who had been followed lon-
gitudinally for at least 1 year. Eligible study designs in-
cluded case series and reports in which patient-level
data were presented in sufficient detail to understand
the age at occurrence and frequency of clinical manifes-
tations, and events of interest (defined below). Animal
and biochemical studies were excluded, as well as arti-
cles published in languages other than English.
Titles and abstracts of articles were independently
screened and categorized as ‘included’, ‘excluded’, or ‘un-
sure’ by two reviewers; any discrepancies were resolved
by a third reviewer who made the final judgment. The
full text of articles meeting the inclusion criteria and
those categorized as ‘unsure’ were analyzed and the arti-
cles were either confirmed to meet the inclusion criteria
or excluded. The reference lists of included studies were
also screened for relevant articles not captured by the
search strategy.
Data extraction
Data from included articles were extracted into an Excel
workbook by two reviewers. If available, demographic
characteristics of the patients described were extracted,
including: age at diagnosis, family history of HPP, age at
loss to follow-up, and age at death (if applicable). Clin-
ical manifestations and events of interest, which were
identified through consultation with four clinical experts
who had experience in treating patients with HPP, as
well as the reported age of their occurrence, were ex-
tracted. Author names, year of publication, study design,
and the specialty of the treating physician were also
included.
The extracted clinical manifestations and events of inter-
est were coded and grouped into the following broad cat-
egories after consultation with the clinical experts: skeletal,
gross motor/ambulatory difficulties, dental, respiratory, or
renal, and are referred to as HPP-related manifestations or
events of interest from here onwards (Additional file 1). In
addition, clinical manifestations and events of interest that
were deemed to contribute to the clinical burden of HPP
were also identified after consultation with clinical experts.
They were defined as those being sufficiently impactful that
they would have likely been described in the case reports
had they occurred. These manifestations and events were
then grouped, focusing on those that would likely have an
important impact on an individual’s activities of daily living,
functional status, or emotional status (Table 1).
Data analysis
Data on clinical manifestations and events were tabu-
lated for all patients identified in the case reports, overall
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and according to the age at first reported occurrence of
HPP manifestations. The age categories were broadly
based on those published by the American Academy of
Pediatrics [17], but were also informed by the underlying
distribution of the data in order to best observe patterns
in disease burden and symptomology: in utero; infancy/
early childhood (aged less than 2 years; sub-divided to
age 0 to less than 0.5 years, and 0.5 to less than 2 years,
for selected outcomes); childhood (aged 2 to less than
10 years); adolescence (aged 10 to less than 18 years) and
adulthood (aged 18 years or older).
Frequency and age at occurrence of all HPP-related clinical
manifestations and events over time
Data derived from cases that had both longitudinal
follow-up of at least 1 year and had experienced one or
more HPP-related manifestations or events of interest
were used to visualize HPP-related clinical manifest-
ation/event patterns and the burden of HPP at the indi-
vidual case level. These data were plotted as grouped
clinical manifestations and event categories over time
using bar charts; one bar chart was generated for each
age group category.
Frequency and age at occurrence of HPP-related
manifestations and events considered to contribute to the
clinical burden of HPP
For cases that had at least 1 year of follow-up available,
the frequency of and age at occurrence of manifestations
and events that contribute to the clinical burden of HPP
were recorded. The number of organ systems (from
Table 1 HPP-related manifestations/events considered to contribute to the clinical burden of HPP
Manifestation/event Description
Premature tooth loss Premature loss of primary and/or permanent teeth
Cranial abnormalities Craniosynostosis, frontal bossing, large anterior fontanel, decreased skull ossification, increased intracranial pressure,
hydrocephalus
Gross motor/ambulation
difficulties
Difficulty walking, gait disturbance, need for mobility devices including wheelchair, other mobility impacts, inability to
work or impairment of activities of daily living
Surgery Any HPP-related surgery (including extremity, cranial, dental, spinal, and other [thoracoscopic epiphysiodesis, osteot-
omy, tracheostomy])
Other dental complications Delayed eruption of teeth, abnormality of the dentition, severe periodontitis, and atrophy of alveolar ridges
Fractures Bone fractures, including pseudofracture and stress fracture
Pain Bone, joint, muscle, and nonspecific/generalized pain
Respiratory symptoms Respiratory compromise, pulmonary hypoplasia, respiratory failure, recurrent respiratory tract infections, and need for
respiratory support
Hospitalizations Hospitalization for any cause
Kidney complications Nephrocalcinosis or renal insufficiency
Seizures Vitamin B6-responsive seizures, seizures of unknown origin and any neurological symptom
Psychological Depressivity, anxiety, insomnia, or other
HPP-related manifestations and events considered to contribute to the clinical burden of HPP were identified by four clinical experts who had experience in
treating patients with HPP
HPP hypophosphatasia
Table 2 Demographic/clinical characteristics and duration of
follow-up of patients with ≥1 year of follow-up
Characteristic Value
Total cases, n (%) 265 (100.0)
Male, n (%) 118 (44.5)
Median (IQR) age at anchor visit, yearsa 4.0 (0.4–34.0)
Reported family history of HPP, n (%) 74 (27.9)
Age at first reported occurrence of HPP manifestations, n (%)
In utero 30 (11.5)
Infancy/early childhood (< 2 years) 101 (38.7)
Childhood (2 to < 10 years) 78 (29.9)
Adolescence (10 to < 18 years) 9 (3.4)
Adulthood (≥ 18 years) 43 (16.5)
Median (IQR) duration of follow-up by age at first reported occurrence
of HPP manifestations, years
Overall 7.0 (3.0–18.0)
In utero 4.0 (2.1–10.3)
Infancy/early childhood (< 2 years) 5.4 (2.4–14.8)
Childhood (2 to < 10 years) 7.7 (3.6–28.5)
Adolescence (10 to < 18 years) 6.0 (4.3–27.0)
Adulthood (≥ 18 years) 15.0 (6.3–27.0)
All patients who had been followed longitudinally for at least 1 year were
included in this analysis
aAnchor visit: first presentation to author of the case report
HPP hypophosphatasia, IQR interquartile range
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skeletal, dental, gross motor, renal, and respiratory) af-
fected by those manifestations and events over time was
also recorded. Kaplan–Meier (K–M) curves were used
to estimate the median (range) age at first occurrence of
the following selected HPP manifestations and events:
premature tooth loss, fracture (one or more fractures),
multiple fractures (three or more fractures), gross
motor/ambulation difficulties, pain, surgery, cranial ab-
normalities, and respiratory symptoms. Censoring was
indicated on the K–M curves to account for the fact that
follow-up times varied owing to the nature of the case
report data, and that the reliability of the estimate of the
proportion of patients who did not experience the out-
come was dependent on the number of individuals not
censored [18]. Death and loss to follow-up were consid-
ered to be censoring events. The three most common
manifestations and events that were reported in each
age group category, regardless of age at first occurrence
of HPP manifestation, were included in this analysis.
Results
Systematic literature review
The PRISMA flow diagram for the selection of eligible
studies is shown in Additional file 2. In total, 3259
abstracts were identified, of which 283 met the study in-
clusion criteria. From the included studies, 511 individ-
ual cases of HPP were identified; longitudinal (at least 1
year) follow-up data were available for 265 of these pa-
tients (Additional file 3). A subset of these patients had
one or more HPP-related manifestations or events of
interest (n = 261; Additional files 1 and 3).
Patient demographics and clinical characteristics
Of the 265 patients with longitudinal follow-up data,
44.5% were male. The median (interquartile range; IQR)
age of the patients at the first presentation to the authors
of the case reports was 4.0 (0.4–34.0) years (Table 2). The
median (IQR) duration of follow-up was 7.0 (3.0–18.0)
years. A family history of HPP was reported for 27.9% of
patients. The first HPP manifestation occurred most fre-
quently during infancy/early childhood (Table 2).
Age at occurrence of all HPP-related clinical
manifestations and events
All HPP-related clinical manifestations and events of
interest were mapped over time for individual patients
who had both longitudinal follow-up of at least 1 year and
had experienced one or more HPP-related manifestations
# of surgeries 0 0 0 1 0 0 0 1 1 1 0 1 0 1 0 0 0 0 0 0 0 2 0 0 0 1 1 0 0 0 0 0 0 0 0 4 0 1 2 0 1 2 0 1 3 0 0
Adult (≥ 18 years)
Adolescence
(10 to < 18 years)
Childhood
(2 to < 10 years)
X X
Infancy/early
childhood
(0 to < 2 years) 
 
 
X X
# of surgeries 0 0 0 0 0 0 0 0 0 0 0 0 0 2 2 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0
X
# of surgeries 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 2 0 0 0 0 1
X
Adult (≥ 18 years)
Adolescence
(10 to < 18 years)
Childhood
(2 to < 10 years)
Early childhood
(0.5 to < 2 years) 
Adult (≥ 18 years)
Adolescence
(10 to < 18 years)
Childhood
(2 to < 10 years)
X
X
a
b
c
Skeletal Dental Gross motor/ambulatory difficulties Respiratory symptoms Renal Resolution of symptoms Not reported Death LTF Anchor visit
Fig. 1 Timing of HPP-related clinical manifestations/events in patients showing first manifestations in (a) infancy, (b) early childhood, and (c)
childhood. a Infancy; 0 to < 0.5 years (n = 47). b Early childhood; 0.5 to < 2 years (n = 54). c Childhood; 2 to < 10 years (n = 78). These graphs are
examples for patients with HPP in infancy, early childhood, and childhood – see Additional file 4 for additional age groups. Cases are ordered by
available follow-up. Only patients who had been followed longitudinally for at least 1 year and who experienced one or more HPP-related
manifestations or events of interest were included in this analysis. ‘Resolution of symptoms’ was reported by the author of the case report. ‘Not
reported’ defined as either nothing reported for the time period or no manifestations of interest. Anchor visit defined as the first point of contact
with the author of the case report. HPP, hypophosphatasia; LTF, lost to follow-up
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or events of interest (n = 261). Evolution of symptomatol-
ogy for individual patients from these case reports whose
first HPP manifestation occurred in infancy, early child-
hood, and childhood is shown in Fig. 1; similar charts
were developed for all age group categories and are in-
cluded in Additional file 4.
The HPP-related symptoms or events of interest expe-
rienced by individual patients often differed between
older and younger patients. For example, many patients
with first HPP manifestations in childhood initially expe-
rienced dental symptoms, while manifestations among
patients in adolescence and adulthood were often pre-
dominantly skeletal (Fig. 1).
Frequency of HPP-related manifestations and events
considered to contribute to the clinical burden of HPP
Of the 265 patients with at least 1 year of longitudinal
follow-up, most (94%) experienced at least one manifest-
ation or event that was considered to contribute to the
clinical burden of HPP during follow-up. The most com-
monly reported clinical manifestations or events across
all age groups were (Table 3): premature tooth loss
(53.5%), fractures (35.8%), pain (33.6%), and gross
motor/ambulation difficulties (30.9%). The three most
frequently reported clinical manifestations or events dur-
ing follow-up for each age at first manifestation group
were: in utero (fracture, cranial abnormalities, and gross
motor/ambulation difficulties), infancy (premature loss
of teeth, cranial abnormalities, and gross motor/ambula-
tion difficulties), childhood (premature loss of teeth,
pain, and fracture), adolescence (pain, premature loss of
teeth, and fracture) and adulthood (pain, multiple frac-
tures, and gross motor/ambulation difficulties). Cranial
abnormalities and respiratory symptoms occurred pre-
dominantly among very young patients (in utero and in-
fancy). Hospitalizations occurred across all age groups
and ranged from 3% (n = 1/30) among patients with
HPP manifestations in utero to 22% (n = 2/9) among pa-
tients with HPP first manifesting in adolescence. Surgical
interventions were more frequently reported in adults
and adolescents than younger age groups.
Age at occurrence of HPP-related manifestations or
events considered to contribute to the clinical burden of
HPP
The median age at first occurrence of cranial abnormal-
ities, pain, respiratory symptoms, premature tooth loss,
fracture, gross motor/ambulation difficulties, and sur-
gery were evaluated. Respiratory symptoms, cranial ab-
normalities, and premature tooth loss were first reported
to occur in infancy and childhood (median age of occur-
rence ranged from 0.3 to 10 years), whereas fractures
Table 3 Proportion of patients with manifestations/events considered to contribute to the clinical burden of HPP
Overall
n (%)
n = 265
In utero
n (%)
n = 30
Infancy
n (%)
n = 102
Childhood
n (%)
n = 78
Adolescence
n (%)
n = 9
Adulthood
n (%)
n = 46
Patients with at least one manifestation/event 248 (94) 25 (83) 96 (94) 78 (100) 9 (100) 40 (87)
Manifestation/event
Premature loss of teeth 142 (53.5) 3 (10.0) 63 (61.8) 58 (74.4) 3 (33.3) 14 (30.4)
One or more fractures 95 (35.8) 12 (40.0) 19 (18.8) 27 (34.6) 3 (33.3) 34 (73.9)
Multiple fracturesa 60 (22.6) 2 (6.7) 13 (12.7) 19 (24.4) 2 (22.2) 24 (52.2)
Pain 89 (33.6) 1 (3.3) 25 (24.5) 32 (41.0) 6 (66.7) 25 (54.3)
Gross motor/ambulation difficulties 82 (30.9) 7 (23.3) 41 (40.2) 18 (23.1) 1 (11.0) 15 (32.6)
Cranial abnormalities 66 (24.9) 12 (40.0) 44 (43.1) 10 (12.8) 0 (0.0) 0 (0.0)
Surgery 64 (24.2) 4 (13.3) 30 (29.4) 8 (10.1) 3 (33.3) 17 (37.0)
Dental otherb 37 (14.0) 0 (0.0) 23 (22.5) 11 (14.1) 0 (0.0) 3 (6.5)
Hospitalizationsc 33 (12.5) 1 (3.3) 18 (17.6) 6 (7.7) 2 (22.2) 6 (13.0)
Respiratory symptomsc 19 (7.2) 5 (16.7) 14 (13.7) 0 (0.0) 0 (0.0) 0 (0.0)
Nephrocalcinosis 11 (4.2) 2 (6.7) 8 (7.8) 1 (1.3) 0 (0.0) 0 (0.0)
Seizures 7 (2.6) 3 (10.0) 3 (2.9) 0 (0.0) 0 (0.0) 1 (2.2)
Renal insufficiency 4 (1.5) 0 (0.0) 1 (1.0) 3 (3.8) 0 (0.0) 0 (0.0)
Psychological 3 (1.1) 0 (0.0) 0 (0.0) 1 (1.3) 0 (0.0) 2 (4.3)
HPP-related manifestations and events considered to contribute to the clinical burden of HPP were identified by four clinical experts who had experience in
treating patients with HPP. Bold italicized numbers indicate the three most frequent symptoms for each age group. Only patients who had been followed
longitudinally for at least 1 year were included in this analysis
aMultiple fractures defined as three or more. bDental other includes delayed eruption of teeth, abnormality of the dentition, severe periodontitis, and atrophy of
alveolar ridges. cOnly patients who survived at least 1 year were included in this analysis
HPP hypophosphatasia
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(one or more, or multiple [three or more]), pain, gross
motor/ambulation difficulties, and surgery occurred in
adulthood (median age of occurrence ranged from 33 to
70 years; Table 4). The median age at first occurrence of
HPP-related manifestations or events, and the possible
evolution of symptomology were found to vary when
these data were evaluated by age at first HPP manifest-
ation (Table 5). In addition, K–M analyses suggested that
the probability of experiencing one of these manifesta-
tions or events increased with age (Figs. 2 and 3). Cra-
nial abnormalities and respiratory symptoms, which are
considered to be the most severe manifestations of HPP,
were more likely to occur below the age of 1 year (only
patients aged less than 5 years were included in this ana-
lysis; Fig. 3). Premature loss of teeth was common in
childhood, but also occurred throughout adolescence
and adulthood (i.e. the loss of permanent teeth). In
pediatric patients with HPP, the median (95% confi-
dence interval [CI]) age at first occurrence of prema-
ture loss of teeth was 3 (2–3) years; first occurrence
of HPP-related surgery, fracture, pain, and gross
motor/ambulation difficulties was between 2 and 13
years (data not shown). Among pediatric patients with
HPP who were followed through adulthood, the risk
of fracture, gross motor/ambulation difficulties, pain,
and surgery in adulthood was high.
Discussion
This is the first study to report a comprehensive review
of published HPP cases to characterize the clinical mani-
festations that are likely to contribute to the burden of
HPP over time. Almost 95% of patients with HPP, re-
gardless of when the disease first manifested, developed
at least one such clinical manifestation or event during
their follow-up. Premature loss of teeth, fracture, and
pain were the most common manifestations. These re-
sults are in line with previous research into the clinical
signs and symptoms associated with HPP, which found
that pain [11, 12], dental abnormalities [13], and
low-trauma fractures [7, 11, 14] were characteristic of
the disease.
Several manifestations and events, such as fractures
(one or more, or multiple), pain, gross motor/ambula-
tory difficulties, and surgery were reported more fre-
quently with increasing age; however, the highest risk of
cranial abnormalities and respiratory symptoms was ob-
served for the youngest patients. These findings are in
agreement with those of previous studies in the litera-
ture that show that severe respiratory impairment and
cranial abnormalities are characteristic of HPP in young
patients [2, 19].
Despite the widespread use of the classification of
HPP based on age at first disease manifestation, it is still
unclear whether these phenotypes reflect separate
Table 4 Median age at first reported occurrence of
manifestations/events considered to contribute to HPP clinical
burden
Manifestation/event Median age, years (range)
Respiratory symptoms 0.3 (0–1)
Cranial abnormalities 1 (0–12)
Premature loss of teeth 10 (0.5–60)
One or more fractures 43 (0–75)
Multiple fracturesa 33 (0–75)
Pain 44 (0–64)
Gross motor/ambulation difficulties 62 (0.2–90)
Surgery 70 (0.1–83)
HPP-related manifestations/events considered to contribute to the clinical
burden of HPP were identified by four clinical experts who had experience in
treating patients with HPP. The data shown are the median age at first
reported occurrence of such manifestations/events across all ages of first HPP
manifestation. Only patients who had been followed longitudinally for at least
1 year were included in this analysis
aMultiple fractures defined as three or more
HPP, hypophosphatasia
Table 5 Median age at first reported occurrence of manifestations/events considered to contribute to HPP clinical burden, by age at
occurrence of first HPP manifestation
Manifestation/event Median age at first manifestation of HPP, years (range)
In utero
n = 30
Infancy
(0 to < 2 years)
n = 102
Childhood
(2 to < 10 years)
n = 78
Adolescence
(10 to < 18 years)
n = 9
Adulthood
(≥ 18 years)
n = 46
Respiratory symptoms 0.1 (0–0.8) 0.4 (0–1) N/A N/A N/A
Cranial abnormalities 1 (0–4) 0.7 (0–12) 5 (1–9) N/A N/A
Pain 1 (1–1) 34 (0–50) 40 (3–56) 42 (10–57) 51 (20–64)
Surgery 2 (0–3) 2 (0.1–30) 59 (1–59) 44 (12–44) 70 (32–83)
Gross motor/ambulation difficulties 2 (0.5–5) 22 (0–54) 18 (1–55) 19 (19–19) 89 (30–90)
Premature loss of teeth 3 (1–4) 3 (0–24) 5 (2–21) 14 (13–17) 25 (6–60)
One or more fractures 15 (0–15) 38 (0–53) 35 (2–55) 53 (15–53) 50 (19–75)
HPP-related manifestations/events considered to contribute to the clinical burden of HPP were identified by four clinical experts who had experience in treating
patients with HPP. Only patients who had been followed longitudinally for at least 1 year were included in this analysis
HPP hypophosphatasia
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disease forms or are different stages of a progressive dis-
ease, particularly with respect to odonto-HPP. Our find-
ing that multiple manifestations and events can
accumulate over time and that the types of manifesta-
tions and events patients’ experience can change, par-
ticularly the evolution from dental abnormalities to
skeletal manifestations later in life, supports the notion
that HPP could be a progressive disease. It also high-
lights the importance of monitoring patients with
HPP-related manifestations closely to identify worsening
of their disease. Moreover, in one case series, eight out
of nine patients who were diagnosed with childhood or
adult-onset HPP and who experienced a substantial dis-
ease burden had initially presented with only dental
manifestations of HPP (premature loss of primary teeth)
as children [15]. This finding could support that
odonto-HPP may be an early manifestation of HPP
rather than a discrete disease entity, as previously
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Fig. 2 Kaplan–Meier curves for time to (a) premature tooth loss, (b) fracturea, (c) multiple fractureb, (d) gross motor/ambulation difficulties, (e)
pain, and (f) surgery. Solid lines show the Kaplan–Meier estimation; grey shading denotes probability of being event-free between upper and
lower 95% CI. Only patients who had been followed longitudinally for at least 1 year were included in this analysis. Patients were censored at first
occurrence of the clinical symptom of interest, death, or loss to follow-up. aTime to first fracture among patients with one or more fractures.
bTime to first fracture among patients with multiple fractures, defined as three or more. CI, confidence interval
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suggested [15]. Prospective long-term observational or
clinical studies would be required to assess disease bur-
den and evolution rigorously. Importantly, improved un-
derstanding of disease burden and evolution may
assist clinicians in identifying the patients with HPP
who are most likely to benefit from enzyme replace-
ment therapy [10].
The rarity of HPP and the limited availability of data re-
strict our understanding of the natural history and burden
of this disease. The findings from this systematic literature
review and synthesis of case reports highlight the novel
approaches required to collate data on rare diseases
where, because of small patient populations, few
large-scale, rigorous observational or clinical studies can
be conducted. Synthesizing case reports allows for the effi-
cient use of available data, ensuring findings of all pub-
lished case reports feed into our current understanding of
the natural history and burden of a disease.
However, the use of case report data has inherent limi-
tations, including the fact that clinical data are not rou-
tinely collected at regular follow-up visits as they would
be in a prospective study. This lack of routinely collected
follow-up data is important to consider when interpret-
ing the findings of this study, particularly with regard to
the impact of early censoring on the precise estimation
of age at first occurrence of manifestations and events
that contribute to the clinical burden of HPP. This is
particularly important for those manifestations and
events occurring later in life, at which time it is likely
that a greater number of patients would have already
been censored. In addition, as a result of publication
bias, reports of patients with mild symptoms or with
symptomology not deemed sufficiently important to de-
scribe may be less likely to be included in the scientific
literature than reports of patients experiencing more
pronounced symptomatology, possibly overestimating
the prevalence of more severe manifestations. On the
other hand, the exclusion of patients who did not sur-
vive beyond 1 year of life likely reduced the actual pro-
portion of patients who were recorded as having been
hospitalized or having respiratory symptoms, underesti-
mating the prevalence of these severe manifestations/
events. Despite these data limitations, we believe that
the analyses undertaken provide valuable insight into the
frequency and timing of manifestations that contribute
to the clinical burden of HPP, given that the generation
of more robust longitudinal data in orphan conditions
like HPP is a major challenge.
Conclusion
This approach using longitudinal, patient-level data col-
lected from case reports is the first of its kind in HPP to
synthesize those data to attempt to build on the current
understanding of the natural history of the disease. Our
findings confirm the high clinical burden of disease
among patients with HPP, regardless of when the disease
first manifests. In addition, we showed that the types of
HPP-related clinical manifestations and events that indi-
viduals’ experience can change over time and multiple
manifestations and events can accumulate over a life-
time. These observations may reflect evolution and pro-
gression of the disease; however, a comprehensive
patient chart review, or similar, is needed to confirm the
insights provided by the present study. The evidence
gaps identified from this literature review can help to in-
form future research priorities that prospectively aim to
characterize HPP-related symptoms that have a potential
impact on disease burden.
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Fig. 3 Kaplan–Meier curves for time to (a) cranial abnormalities and (b) respiratory symptoms in patients with these manifestations or events.
Solid lines show the Kaplan–Meier estimation; grey shading denotes probability of being event-free between upper and lower 95% CI. Owing to
the distribution of the data, only patients who had been followed longitudinally for at least 1 year and had experienced cranial abnormalities
and/or respiratory systems before the age of 5 years were included in this analysis. The x axes in panels a and b are restricted to 5 years and 1
year, respectively. Patients were censored at first occurrence of the clinical symptom of interest, death, or loss to follow-up. CI, confidence interval
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Additional files
Additional file 1: HPP-related clinical manifestation and event
categories. (DOCX 15 kb)
Additional file 2: PRISMA flow diagram presenting the selection of
eligible studies. PRISMA, Preferred Reporting Items for Systematic Reviews
and Meta-Analyses. (EPS 1824 kb)
Additional file 3: Schematic illustrating the cohorts of patients with HPP
included in the different analyses. HPP, hypophosphatasia. (EPS 1798 kb)
Additional file 4: Timing of HPP-related clinical manifestations/events in
patients showing first manifestations in (a) utero, (b) adolescence, and (c)
adulthood. a In utero (n = 30). b Adolescence; 10 to < 18 years (n = 9).
c Adulthood; i 18–39 years (n = 22) and ii≥ 40 years (n = 21). Cases are
ordered by available follow-up. Only patients who had been followed longi-
tudinally for at least 1 year and who experienced one or more HPP-related
manifestations or events of interest were included in this analysis. ‘Reso-
lution of symptoms’ was reported by the author of the case report. ‘Not
reported’ defined as either nothing reported for this time period or no
manifestations of interest. Anchor visit defined as the first point of contact
with the author of the case report. HPP, hypophosphatasia; LTF, lost to
follow-up. (EPS 2093 kb)
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